- Home
- CAPS vs SNGX Comparison
CAPS vs SNGX Comparison
Compare CAPS & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPS
- SNGX
- Stock Information
- Founded
- CAPS 1987
- SNGX 1987
- Country
- CAPS United States
- SNGX United States
- Employees
- CAPS N/A
- SNGX N/A
- Industry
- CAPS
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CAPS
- SNGX Health Care
- Exchange
- CAPS NYSE
- SNGX Nasdaq
- Market Cap
- CAPS 7.4M
- SNGX 6.5M
- IPO Year
- CAPS N/A
- SNGX 1987
- Fundamental
- Price
- CAPS $1.60
- SNGX $1.32
- Analyst Decision
- CAPS
- SNGX Strong Buy
- Analyst Count
- CAPS 0
- SNGX 1
- Target Price
- CAPS N/A
- SNGX $6.00
- AVG Volume (30 Days)
- CAPS 93.7K
- SNGX 2.7M
- Earning Date
- CAPS 04-02-2025
- SNGX 08-08-2025
- Dividend Yield
- CAPS N/A
- SNGX N/A
- EPS Growth
- CAPS N/A
- SNGX N/A
- EPS
- CAPS N/A
- SNGX N/A
- Revenue
- CAPS $43,416,000.00
- SNGX $2,342.00
- Revenue This Year
- CAPS $7.87
- SNGX N/A
- Revenue Next Year
- CAPS N/A
- SNGX N/A
- P/E Ratio
- CAPS N/A
- SNGX N/A
- Revenue Growth
- CAPS N/A
- SNGX N/A
- 52 Week Low
- CAPS $1.30
- SNGX $1.09
- 52 Week High
- CAPS $16.18
- SNGX $5.40
- Technical
- Relative Strength Index (RSI)
- CAPS N/A
- SNGX 41.75
- Support Level
- CAPS N/A
- SNGX $1.34
- Resistance Level
- CAPS N/A
- SNGX $1.46
- Average True Range (ATR)
- CAPS 0.00
- SNGX 0.11
- MACD
- CAPS 0.00
- SNGX 0.03
- Stochastic Oscillator
- CAPS 0.00
- SNGX 62.16
About CAPS CAPSTONE HOLDING CORP
Capstone Holding Corp is a building products distribution network. The existing network is comprised of Instone, a distributor of thin veneer stone and related masonry products in the United States, serving both residential and commercial construction markets. The company's product offering includes manufactured and natural stone products, supported by a distribution network. The company's current products include stone veneer, landscape stone, and modular masonry fireplaces.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).